BULLSEYE研究:177Lu-PSMA-617治疗寡转移性激素敏感性前列腺癌的随机II期试验
BULLSEYE是一项开放标签随机II期试验,纳入58例PSMA表达寡转移激素敏感性前列腺癌患者,比较177Lu-PSMA-617与延迟ADT的疗效。
要点
- 干预组前30周进展率7%,对照组93%。
- 治疗相关不良事件以1级口干、乏力、恶心为主,无4级事件。
核心结论
- 177Lu-PSMA-617在寡转移性激素敏感性前列腺癌中显示出有前景的缓解率和延迟疾病进展的效果,且大多数治疗相关不良事件为低级别。
研究设计与样本
- BULLSEYE为开放标签、随机、II期试验,在荷兰三家学术医院和塞浦路斯一家社区医院开展。
- 纳入58例男性患者(干预组29例,对照组29例),随机1:1分配至177Lu-PSMA-617组或标准延迟ADT对照组。
主要发现
- 干预组1例(3%)出现3级干眼症,经支持治疗缓解;3例(10%)出现3级淋巴细胞计数下降。
- 对照组5例(17%)出现3级高血压,1例(3%)3级淋巴细胞计数下降,1例(3%)4级胆囊感染,1例(3%)4级心肌梗死。
- 治疗组最常见不良事件为1级口干(19例,66% vs 对照组3例,10%)、乏力(16例,55% vs 6例,21%)、恶心(14例,48% vs 3例,10%)。
关键数值与推荐
- 干预组中位接受4周期(IQR 4-4)177Lu-PSMA-617。
- 数据截止2025年3月31日,中位随访27个月(IQR 18-32)。
- 未报告治疗相关4级不良事件或死亡;干预组未报告严重不良事件。
临床怎么用
- 对于PSMA表达寡转移性激素敏感性前列腺癌患者,177Lu-PSMA-617可能作为延迟ADT的一种治疗选择,但需进一步研究确认。
- 治疗期间需监测口干、乏力、恶心及淋巴细胞计数等不良事件。
局限性
- 样本量较小(58例),为II期试验。
- 开放标签设计。
- 随访时间有限(中位27个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 (177Lu-PSMA-617) is a novel treatment for metastatic castration-resistant prostate cancer. Here, we aimed to evaluate 177Lu-PSMA-617 in patients with PSMA-expressing oligometastatic hormone-sensitive prostate cancer (HSPC). METHODS: BULLSEYE was an open-label, randomised, phase 2 trial in three academic hospitals in the Netherlands (Radboud University Medical Center, University Medical Center Groningen, and University Medical Center Amsterdam) and one community hospital in Cyprus (German Oncology Center). Eligible participants were men, aged 18 years or older, with biochemically recurrent prostate cancer following radical prostatectomy or radiotherapy, Eastern Cooperative Oncology Group performance status score of 0-1, a PSA doubling time of less than 6 months and PSA amounts of over 1·0 μg/L. Paients aged 18 years or older with recurrent hormone sensitive prostate cancer following radical surgery or radiotherapy were randomly asigned (1:1) using a centralised web-based system with block randomisation to 177Lu-PSMA-617 (intervention) or standard of care (control) of deferred androgen deprivation therapy (ADT). The treatment group received two cycles of 7·4 GBq 177Lu-PSMA-617 every 6 weeks. 6 weeks after the second treatment cycle, patients with residual PSMA-expressing disease on PSMA-PET-CT, and no grade 3 or worse treatment-related adverse events received two additional cycles of 7·4 GBq 177Lu-PSMA-617 given 6 weeks apart.The control group did not receive treatment but underwent active monitoring for disease progression. Co-primary endpoints were the proportion of patients with disease progression, and time to disease progression with the same endpoint. Primary, secondary, and safety endpoints were assessed in the per-protocol population, who all received at least one 1 dose of 177Lu-PSMA-617. This trial is registered with ClinicalTrials.gov (NCT04443062) and has completed accrual. FINDINGS: Between April 20, 2020, and July 29, 2024, 78 males were screened and 58 were eligible (29 intervention and 29 control). 56 patients were white, one was Asian, and one was African. Patients in the intervention group received a median of four cycles (IQR 4-4) of 177Lu-PSMA-617. At data cutoff (March 31, 2025), median follow-up time was 27 months (IQR 18-32). During the first 30 weeks, disease progression was reported in two (7%) of 29 patients in the intervention group versus 27 (93%) of 29 patients in the control group (p<0·0001). Median progression-free survival (per-protocol) was 25 months (IQR 15 to not reached) for intervention group versus 5 months (IQR 3-7) for control (hazard ratio [HR] 0·07, 95% CI 0·03-0·17; p<0·0001). One (3%) patient in the intervention group developed grade 3 dry eyes, which resolved with supportive treatment, and grade 3 lymphocyte count decrease was observed in three (10%) patients in the treatment group. The control group had five (17%) patients with grade 3 hypertension, one (3%) patient with a grade 3 decrease in lymphocyte count, one (3%) patient with a grade 4 gallbladder infection, and one (3%) patient with a grade 4 myocardial infarction. There were no treatment-related grade 4 adverse events or deaths. No serious adverse events were reported in patients who received 177Lu-PSMA-617. The most common adverse events were grade 1 dry mouth in 19 (66%) patients in the treatment group versus three (10%) patients in the control group, fatigue in 16 (55%) patients in the treatment group versus six (21%) patients in the control group, and nausea in 14 (48%) patients in the treatment group versus three (10%) patients in the control group. No deaths were attributed to the treatment in either group. INTERPRETATION: 177Lu-PSMA-617 showed promising response rates and delayed disease progression in patients with oligometastatic HSPC in this trial. In addition, most treatment-related adverse events were low grade. FUNDING: Dutch Prostate Cancer Foundation (Prostaatkankerstichting) and Novartis.
引用
- Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol. 2026. PMID: 41926960. doi:10.1016/S1470-2045(25)00762-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。